Acting on minimal residual disease in ALL
- PMID: 24924992
- DOI: 10.1016/S1470-2045(14)70280-3
Acting on minimal residual disease in ALL
Comment in
-
MRD stratification for paediatric ALL.Lancet Oncol. 2014 Sep;15(10):e415-6. doi: 10.1016/S1470-2045(14)70337-7. Lancet Oncol. 2014. PMID: 25186043 No abstract available.
Comment on
-
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9. Lancet Oncol. 2014. PMID: 24924991 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources